Key results from new tiotropium studies in COPD and asthma to be presented at ERS 2012

New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic.

INGELHEIM, Germany (prHWY.com) August 26, 2012 - First Phase III exacerbation and lung function data for tiotropium via the Respimat® inhaler in asthmaA
New Phase II data on combination of tiotropium and olodaterol administered by Respimat® in COPDB

New data to be presented at the Annual Congress of the European Respiratory Society (ERS 2012), in Vienna, Austria, will shed light on the current and potential future role of tiotropium, the first once-daily long-acting inhaled anticholinergic for patients with Chronic Obstructive Pulmonary Disease (COPD).

Highlights from the accepted abstracts include the first Phase III exacerbation and lung function data for Boehringer Ingelheim's and Pfizer's tiotropium in asthma. These results derive from two replicate studies evaluating the efficacy of once-daily tiotropium administered by the Respimat® Soft MistTM Inhaler (SMI) in patients with severe asthma who remain symptomatic on at least ICSC/LABAD. The data are relevant since a significant proportion of patients with asthma remain symptomatic despite current treatment options and may have asthma exacerbations.1

A further presentation will focus on results from a Phase II study that investigates the potential of a future fixed-dose combination (FDC) of tiotropium and Boehringer Ingelheim's once-daily LABA olodaterol in patients with COPD. This Phase II trial was looking at the impact of different doses of tiotropium and olodaterol as a free combination on lung function, both administered individually by the Respimat® SMI. Boehringer Ingelheim has already started to evaluate the tiotropium and olodaterol FDC in the TOviTOTM Phase III clinical trial programme.

In addition, a new analysis of the four year UPLIFTTM data will be presented. This study evaluated the effect of tiotropium (18 µg via HandiHaler®) in low risk patients based on the newly defined patient groups in the updated report of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). It will further add to the wealth of data for tiotropium in COPD, which has now been investigated in 175 clinical trials in COPD.

The ERS congress is the largest respiratory meeting in the World, with attendance from more than 100 countries.2 All tiotropium abstracts can be accessed through the ERS website, http://www.erscongress2012.org/.

Asthma

Topic


Lead Author


Presentation details


Exacerbation data from two Phase III studies evaluating efficacy of once-daily tiotropium in severe asthma patients symptomatic despite ICS/LABA therapy


HAM Kerstjens


Poster discussion

Monday 3rd September

08.30-10.30


Lung function data from two Phase III studies evaluating efficacy of once- daily tiotropium in severe asthma patients symptomatic despite ICS/LABA therapy


HAM Kerstjens


Poster session

Monday 3rd September

12.50-14.40



COPD

Topic


Lead Author


Presentation details


Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD


R Aalbers


Poster discussion

Monday 3rd September

14.45-16.45


Effectiveness of tiotropium in low-risk patients according to new GOLD severity grading


D Halpin


Poster session

Monday 3rd September

12.50-14.40



- Ends -

###

Tag Words: None

Categories: Health

Link To This Press Release:

URL HTML Code